Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:49 UTC |
---|
Update Date | 2022-03-07 02:51:39 UTC |
---|
HMDB ID | HMDB0014548 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Alprazolam |
---|
Description | Alprazolam is only found in individuals that have used or taken this drug. It is a triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of panic disorders, with or without agoraphobia, and in generalized anxiety disorders. (From AMA Drug Evaluations Annual, 1994, p238)Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell. |
---|
Structure | CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12 InChI=1S/C17H13ClN4/c1-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-13(18)7-8-15(14)22(11)16/h2-9H,10H2,1H3 |
---|
Synonyms | Value | Source |
---|
8-Chloro-1-methyl-6-phenyl-4H-S-triazolo(4,3-a)(1,4)benzodiazepine | ChEBI | Xanax | ChEBI | TUS-1 | HMDB | Alphapharm brand OF alprazolam | HMDB | Alprazolam orion brand | HMDB | Alprazolam pfizer brand | HMDB | Apotex brand OF alprazolam | HMDB | Kalma | HMDB | Kenral brand OF alprazolam | HMDB | Nu alpraz | HMDB | Pfizer brand OF alprazolam | HMDB | Temmler brand OF alprazolam | HMDB | Trankimazin | HMDB | Alprazolam kenral brand | HMDB | Alprazolam novopharm brand | HMDB | Alprazolam nu-pharm brand | HMDB | Apo alpraz | HMDB | Apo-alpraz | HMDB | Arzneimittelwerk dresden brand OF alprazolam | HMDB | Cassadan | HMDB | NuAlpraz | HMDB | Alprazolam alphapharm brand | HMDB | ApoAlpraz | HMDB | Novo alprazol | HMDB | Novo-alprazol | HMDB | NovoAlprazol | HMDB | Nu pharm brand OF alprazolam | HMDB | Nu-pharm brand OF alprazolam | HMDB | Alprazolam apotex brand | HMDB | Alprazolam temmler brand | HMDB | Alprazolan | HMDB | Alprox | HMDB | D-65MT | HMDB | D65MT | HMDB | Esparon | HMDB | Novopharm brand OF alprazolam | HMDB | Nu-alpraz | HMDB | Orion brand OF alprazolam | HMDB | Ralozam | HMDB | Tafil | HMDB |
|
---|
Chemical Formula | C17H13ClN4 |
---|
Average Molecular Weight | 308.765 |
---|
Monoisotopic Molecular Weight | 308.082874143 |
---|
IUPAC Name | 12-chloro-3-methyl-9-phenyl-2,4,5,8-tetraazatricyclo[8.4.0.0²,⁶]tetradeca-1(10),3,5,8,11,13-hexaene |
---|
Traditional Name | neurol |
---|
CAS Registry Number | 28981-97-7 |
---|
SMILES | CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12 |
---|
InChI Identifier | InChI=1S/C17H13ClN4/c1-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-13(18)7-8-15(14)22(11)16/h2-9H,10H2,1H3 |
---|
InChI Key | VREFGVBLTWBCJP-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as 1,2,4-triazolo[4,3-a][1,4]benzodiazepines. These are aromatic compounds containing a 1,4-benzodiazepine fused to and sharing a nitrogen atom with a 1,2,4-triazole ring. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Benzodiazepines |
---|
Sub Class | 1,4-benzodiazepines |
---|
Direct Parent | 1,2,4-triazolo[4,3-a][1,4]benzodiazepines |
---|
Alternative Parents | |
---|
Substituents | - 1,2,4-triazolo[4,3-a][1,4]benzodiazepine
- Aryl chloride
- Aryl halide
- Monocyclic benzene moiety
- Benzenoid
- Azole
- 1,2,4-triazole
- Heteroaromatic compound
- Ketimine
- Propargyl-type 1,3-dipolar organic compound
- Organic 1,3-dipolar compound
- Azacycle
- Organopnictogen compound
- Organic nitrogen compound
- Organonitrogen compound
- Organochloride
- Organohalogen compound
- Imine
- Hydrocarbon derivative
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 228 - 228.5 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.032 g/L | Not Available | LogP | 4.9 | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross SectionsAdduct Type | Data Source | CCS Value (Å2) | Reference |
---|
[M+H]+ | CBM | 171.5 | 30932474 |
|
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatized |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Alprazolam GC-MS (Non-derivatized) - 70eV, Positive | splash10-002f-4090000000-d08d3360d39ebeeb87f8 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Alprazolam GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-0kdi-4792000000-9f1cdda14e36000955d3 | 2014-09-20 | Not Available | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Alprazolam LC-ESI-qTof , Positive-QTOF | splash10-0a4i-0910000000-9efa6a8a3dea17fc1ce7 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Alprazolam LC-ESI-QTOF , positive-QTOF | splash10-0a59-0079000000-e4c35fb4df41aa5cc62e | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Alprazolam , positive-QTOF | splash10-0bt9-0169000000-0e6779728f3bdec2acf1 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Alprazolam , positive-QTOF | splash10-0a4i-0910000000-9efa6a8a3dea17fc1ce7 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Alprazolam -1V, Positive-QTOF | splash10-0a59-0069000000-a0ce5531f8b2cb70eb28 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Alprazolam 35V, Positive-QTOF | splash10-0a59-0097000000-5b89356bc4e59b202968 | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alprazolam 10V, Positive-QTOF | splash10-0a4i-0009000000-be2bb3a7878fa113efc8 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alprazolam 20V, Positive-QTOF | splash10-0a4i-0039000000-7bd62157388fecd0e430 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alprazolam 40V, Positive-QTOF | splash10-0o93-3390000000-307fd2f8dd5a9c4f7eac | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alprazolam 10V, Negative-QTOF | splash10-0a4i-0029000000-ceec7f24f309605ec6fb | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alprazolam 20V, Negative-QTOF | splash10-0a4i-0097000000-d61397bd13173381fc0d | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alprazolam 40V, Negative-QTOF | splash10-0udi-3290000000-370bd9e4b8fa73925c04 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alprazolam 10V, Negative-QTOF | splash10-0a4i-0009000000-4c14e6d547df7e93b204 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alprazolam 20V, Negative-QTOF | splash10-0a4i-0019000000-4e5c057a93f515a3aad6 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alprazolam 40V, Negative-QTOF | splash10-001i-9021000000-63a97e91d4073b1a51cb | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alprazolam 10V, Positive-QTOF | splash10-0a4i-0009000000-f3356a9af159cd5dbe12 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alprazolam 20V, Positive-QTOF | splash10-0a4i-0009000000-f3356a9af159cd5dbe12 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alprazolam 40V, Positive-QTOF | splash10-004i-1090000000-a69b3052aba45b714693 | 2021-09-24 | Wishart Lab | View Spectrum |
|
---|
General References | - Wolf B, Griffiths RR: Physical dependence on benzodiazepines: differences within the class. Drug Alcohol Depend. 1991 Dec 31;29(2):153-6. [PubMed:1686752 ]
- Haque W, Watson DJ, Bryant SG: Death following suspected alprazolam withdrawal seizures: a case report. Tex Med. 1990 Jan;86(1):44-7. [PubMed:2300914 ]
- Risse SC, Whitters A, Burke J, Chen S, Scurfield RM, Raskind MA: Severe withdrawal symptoms after discontinuation of alprazolam in eight patients with combat-induced posttraumatic stress disorder. J Clin Psychiatry. 1990 May;51(5):206-9. [PubMed:2335496 ]
- Hori A: Pharmacotherapy for personality disorders. Psychiatry Clin Neurosci. 1998 Feb;52(1):13-9. [PubMed:9682928 ]
- Garcia-Algar O, Lopez-Vilchez MA, Martin I, Mur A, Pellegrini M, Pacifici R, Rossi S, Pichini S: Confirmation of gestational exposure to alprazolam by analysis of biological matrices in a newborn with neonatal sepsis. Clin Toxicol (Phila). 2007;45(3):295-8. [PubMed:17453885 ]
|
---|